UChicago Medicine First Site in Illinois Offering Pioneering CAR T-Cell Therapy for Cancer – Newswise (press release)
|
UChicago Medicine First Site in Illinois Offering Pioneering CAR T-Cell Therapy for Cancer
Newswise (press release) Newswise — The U.S. Food and Drug Administration today approved the use of a breakthrough cancer treatment — Yescarta (axicabtagene ciloleucel) — for adult patients with relapsed or refractory diffuse large B-cell lymphoma, a form of non-Hodgkin … FDA Approves Yescarta™, Revolutionary CAR-T Immunotherapy for … FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma FDA Approves Axi-Cel for Large B-cell Lymphoma |
